Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients )
Phase of Trial: Phase IV
Latest Information Update: 18 Jan 2019
Price : $35 *
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms APERCU
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 17 Jun 2016 Status changed from active, no longer recruiting to recruiting.
- 02 May 2016 Status changed from recruiting to active, no longer recruiting.